Agilent Technologies, Inc. · NYSE:A

Agilent Technologies — Q1 2024 Earnings Presentation

9 slides from Agilent Technologies's earnings presentation, Feb 27, 2024

  1. Slide 1: Agilent Technologies Q1'24 Financial Results Overview

    Agilent Technologies Q1’24 Financial Results Overview

  2. Slide 2: Safe Harbor

    Safe Harbor These presentations contain forward-looking statements (including, without limitation, information, and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth

  3. Slide 3: Agilent Results Q1'24

    Agilent Results Q1’24 Q1’24 Financial Metrics Q1’24 Highlights • Revenues: $1.66B, -5.6% reported, • Growth: Revenue declined as growth in services and consumables was more -6.4% y/y core(1)(2) (+0.9% FX,-0.1% M&A). than offset by conservative capital equipment spending across most end markets. We a

  4. Slide 4: Q1 FY'24 Core Growth Results by End Market

    Q1 FY’24 Core Growth(2) Results by End Market Agilent’s Diversified business sees key drivers continue to outperform under challenging market conditions  Pharma: Down -12% overall, with +2% BioPharma growth ex-China led by services and consumables, offset by weakness in China and dampened instrumen

  5. Slide 5: Life Sciences & Applied Markets Group (LSAG)

    Life Sciences & Applied Markets Group (LSAG) Instrumentation, Informatics, and • Better than expected Q1 revenue driven by a larger Consumables Lunar New Year timing impact in China, strength in for Analytical Laboratories applied markets and consumables, while continuing to see a conservative envir

  6. Slide 6: Agilent CrossLab Group (ACG)

    Agilent CrossLab Group (ACG) Analytical Laboratory • CrossLab continues to deliver despite Services the challenging market conditions, growing +5% with mid-single digit growth or better performance in all end markets and geographic regions except China. • Contract revenue continues to be robust with

  7. Slide 7: Diagnostics and Genomics Group (DGG)

    Diagnostics and Genomics Group (DGG) Pathology, Genomics, and Nucleic Acid Manufacturing • Q1’24 revenue declined due to continued softness in NGS reagents and an increased clinical business mix at NASD, while the Pathology business delivered mid-single digit growth. • Announced the release of the A

  8. Slide 8: Q2'24 and FY'24 Guidance and Forward-looking Considerations

    Q2’24 and FY’24 Guidance and Forward-looking Considerations Based on Forecasted Currency Exchange Rates Q2’24 Guidance (1) FY’24 Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,560 $1,590 Net Revenue ($M) $6,710 $6,810 Y/Y Core Revenue Growth (2) -8.4% -6.7% Y/Y Core Revenue Growt

  9. Slide 9: Q1'24 Financial Results Overview

    2/27/2024 Q1'24 Financial Results Overview

Agilent Technologies — Q1 2024 Earnings Presentation on 6ix